News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Insider Monkey49d agoneutral
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?Simply Wall St.53d agoneutral
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run?Investor's Business Daily58d agobearish
When To Sell Stocks: Why Investors May Want To Walk Away From These IBD 50 StocksInvestorsHub67d agoneutral
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in FocusSimply Wall St.73d agoneutral
Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair ValueStockStory85d agoneutral
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings CallStockStory89d agobullish
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded GuidanceSimply Wall St.92d agobullish
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting BuybacksSimply Wall St.92d agobullish
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?GuruFocus.com93d agoneutral
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...